IFIH1 and secondary hemophagocytic lymphohistiocytosis: Interestingly, severe COVID-19 disease presents a fairly similar clinical and cytokine profile to other diseases such as secondary hemophagocytic lymphohistiocytosis (sHLH) [15] or clinically amyopathic dermatomyositis (CADM) associated with anti-melanoma differentiation-associated gene 5 (MDA-5), where calcineurin inhibitors such as tacrolimus or cyclosporine play a central role in its treatment [16].